All In Biotech

Free tool

FAERS Monitor: Talicia

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213004 or its brand name (Talicia, Amoxicillin, Omeprazole Magnesium, Rifabutin). Reports on generic versions are filed under their own applications.

Reports

219

Serious

30

14% of reports

Hospitalization

10

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective32
  • rash25
  • treatment failure21
  • headache18
  • nausea18
  • diarrhoea16
  • fatigue16
  • pain11
  • vomiting11
  • abdominal pain10
  • dizziness10
  • pruritus9
  • abdominal pain upper8
  • dyspepsia8
  • pyrexia8

Reports by year received

View as table
YearReports
202017
202156
202250
202352
202426
202516
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,940 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
treatment failureSignal2124.416.2449
dyspepsiaSignal87.84.041
rashSignal255.53.890
abdominal painSignal104.12.321
abdominal pain upperSignal83.71.914
headacheSignal182.81.819
diarrhoeaSignal162.41.512
drug ineffectiveSignal322.31.725
pruritusSignal92.21.25
vomitingSignal112.21.37
pyrexiaSignal82.21.14
nauseaSignal182.21.411
fatigue162.01.27
dizziness101.91.14
pain111.71.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.